Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes that VMAT2 inhibitors are not... Read More

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT ( 7:00 AM ET ) in London Piper Sandler 37 th Annual Healthcare Conferenc e. Fireside chat on Tuesday, December 2, 2025 at 9:30 AM ET... Read More

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated This Phase 2 signal-seeking study enrolled 73 adult patients with a diagnosis... Read More

Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA ® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY ® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms SAN DIEGO , Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today... Read More

Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement Scale Total Score INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor that allows patients to start immediately... Read More

Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on October 28, 2025 . The schedule for the press release and conference call / webcast is as follows: Q3 2025 Press... Read More

SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marketing strategy for Neurocrine's... Read More

Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders ® SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ® -HD2 study demonstrating an established long-term safety profile,... Read More

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported. Patients who achieved symptomatic remission had robust improvements across multiple patient-reported... Read More

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845). In recognition of the data presentation, Neurocrine was honored with... Read More

Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place... Read More

SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy , Chief Commercial Officer Eric Benevich , and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m. ET on Wednesday, September 3, 2025 . Chief Executive Officer Kyle Gano... Read More

SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45 th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025 . Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at... Read More

Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA ® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY ® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO , July 30, 2025 /PRNewswire/ -- Neurocrine... Read More

Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO , July 15, 2025 /PRNewswire/ -- PicnicHealth , a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), the CAHtalog ® Registry, identified an... Read More

Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journey Real-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid doses SAN DIEGO , July... Read More

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY ® (crinecerfont) achieved clinically meaningful weight reductions Substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatment SAN DIEGO , July 14, 2025 /PRNewswire/ - - Neurocrine Biosciences, Inc. (Nasdaq: NBIX)... Read More

One-year data from CAHtalyst ™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst ™ Pediatric study SAN DIEGO , July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the... Read More

Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO , July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on July 30, 2025 . The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press... Read More

SAN DIEGO , June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a... Read More

Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placebo Findings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress SAN DIEGO , June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT ® -HD study highlighting... Read More

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American Association of Nurse Practitioners (AANP) National Conference SAN DIEGO , June 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal... Read More

SAN DIEGO , June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025 . Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a... Read More

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment... Read More

SAN DIEGO , May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-1117568 is the first and only investigational oral muscarinic M4 selective... Read More

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in... Read More

Patients Treated with INGREZZA ® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study... Read More

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions Findings Presented at the 2025 American Association of Clinical Endocrinology Annual Meeting SAN DIEGO , May 15, 2025 /PRNewswire/ --... Read More

Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes Findings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting SAN DIEGO , May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) presented today a systematic literature review illustrating the... Read More

Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology SAN DIEGO , May 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new results from subgroup... Read More

SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 11:20 AM Pacific Time in Las Vegas . Chief Financial Officer Matt Abernethy and Chief Commercial... Read More

New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO , May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health... Read More

INGREZZA ® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITY TM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of... Read More

Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements 1 SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia... Read More

SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia... Read More

Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern SAN DIEGO , April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT ® 3 extension and KINECT ® 4, demonstrating the long-term safety... Read More

Conference Call and Webcast Scheduled for Monday, May 5 SAN DIEGO , April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on May 5, 2025 . The schedule for the press release and conference call / webcast is as follows: Q1 2025 Press Release: May... Read More

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani , M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025 . Dr. Keswani, an accomplished... Read More

All Patients Treated with INGREZZA ® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting SAN DIEGO , March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation... Read More

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive dyskinesia among the majority of... Read More

Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium SAN DIEGO , March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT ® -HD study showcasing significant improvements in chorea across body regions with... Read More

SAN DIEGO , March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday , March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com . A replay of the... Read More

SAN DIEGO , March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2... Read More

SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA ® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO... Read More

SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano , Chief Financial Officer Matt Abernethy , and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston . Chief Financial Officer Matt... Read More

SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October... Read More

INGREZZA ® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion , Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA ® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITY TM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United... Read More

Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO , Jan. 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on February 6, 2025 . The schedule for the press release and conference call / webcast is as follows: Q4... Read More

SAN DIEGO , Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase 2 SAVITRI™ study of... Read More

Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO , Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended... Read More

SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz , Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the continued transformation of Neurocrine's Chemistry, Manufacturing and... Read More

SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) , sponsored by the company . The supplement, titled " Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency... Read More

Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced... Read More

SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43 rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco . Kyle Gano , Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com . A replay of... Read More

CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers SAN DIEGO... Read More

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in... Read More

The 7 th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano , Chief Financial Officer Matt Abernethy , and Vice-President of Investor Relations Todd Tushla will present at: The 7 th... Read More

Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT ® -HD study showing the impact of INGREZZA ® (valbenazine) capsules on emotional health and psychiatric stability in... Read More

2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November. Chief Executive Officer Kyle Gano , Chief Financial Officer Matt Abernethy , and Vice-President of Investor Relations... Read More

Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA ® (valbenazine) capsules . These data showed significant improvements in functional, social, emotional and health-related quality of life measures in... Read More

SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT ® -4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA ® (valbenazine) capsules treatment. This research, "Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment" (Poster #98), was shared at the 2024 Psych... Read More

INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO , Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2024 and... Read More

Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on October 30, 2024 . The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press... Read More

KINECT ® -HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders ® SAN DIEGO , Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)... Read More

SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4 th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday , September 26, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. The live presentation will... Read More

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects Neurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for... Read More

SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on Tuesday , September 17, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano , Chief Financial Officer Matt Abernethy , and Vice-President of Investor Relations Todd Tushla will present at the conference. The... Read More

Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September. Chief Executive Officer Kevin Gorman , Chief Business Development and Strategy Officer Kyle Gano , and Chief Financial Officer... Read More

The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from Baseline The Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder... Read More

SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44 th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesday , August 14, 2024. Kyle Gano , Chief Business Development and Strategy Officer, and Todd Tushla , Vice President of Investor Relations, will present at the conference. The live presentation will be webcast and may be accessed... Read More

INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO , Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second... Read More

SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA ® (valbenazine) capsules , the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. 1 INGREZZA ® SPRINKLE (valbenazine) capsules is now available... Read More

Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on August 1, 2024 . The schedule for the press release and conference call / webcast is as follows: • Q2 2024 Press... Read More

PDUFA Target Action Dates in Late December 2024 Highly Selective CRF 1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO , July 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents... Read More

SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024 , including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients... Read More

CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control 30% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose at Week 28 while Maintaining Androgen... Read More

CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control 62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining... Read More

Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45 th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO , May 29, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June. Kevin Gorman , Chief Executive Officer, Kyle Gano , Chief Business Development and Strategy Officer, and Matt Abernethy , Chief Financial... Read More

Board of Directors appoints Kyle Gano , Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman , Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO , May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman , Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024 . Kyle... Read More

New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase 2 (CHAMPAIN) Study Data for MRHC vs. Plenadren in Primary Adrenal Insufficiency Long-Term Study Data for MRHC in Adults with CAH SAN DIEGO , May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today... Read More

SAN DIEGO , May 21, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT ® -4 study of INGREZZA ® (valbenazine) capsules in the Journal of Clinical Psychopharmacology . The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants... Read More

CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal Insufficiency Demonstrated Participants Achieved Physiological Morning Cortisol Levels after 4 Weeks Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Adults with CAH Demonstrated Reduction in Median... Read More

CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients Comprehensive Literature Review Identified Potential Psychological and Cognitive Impact of High Glucocorticoid Doses in CAH Patients SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will... Read More

SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the... Read More

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment... Read More

SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time ( 2:20 p.m. Eastern Time ) on Tuesday May 14, 2024 in Las Vegas . Kevin Gorman , Chief Executive Officer, Matt Abernethy , Chief Financial Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will present at the conference. The live... Read More

CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort ® /Efmody ® ) in Adrenal Insufficiency Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today... Read More

Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed 1-3 The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication 4 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living... Read More

CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH) CAHtalog™ Registry Data of Glucocorticoid Treatment Patterns in Pediatric and Adult Patients Illustrates the Challenges of Long-Term CAH Management SAN DIEGO , May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™... Read More

INGREZZA ® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA ® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major... Read More

SAN DIEGO , April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA ® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA ® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. 1 INGREZZA SPRINKLE provides an alternative... Read More

WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research. SAN DIEGO , April 24, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?! , an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal... Read More

SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Score at Day 56 NBI-1065845 Was Generally Well-Tolerated SAN DIEGO , April 23, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its... Read More

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences , Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug... Read More

Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO , April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on May 1, 2024 . The schedule for the press release and conference call / webcast is as follows: • Q1 2024 Press Release:... Read More

SAN DIEGO , April 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B... Read More

SAN DIEGO , March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is an investigational, oral, selective inhibitor of the vesicular monoamine transporter-2 (VMAT2) for the potential... Read More

UBS Virtual CNS Day 2024 Conference on March 18 Stifel 2024 Virtual CNS Days Conference on March 19 SAN DIEGO , March 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming virtual investor conferences in March. Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will present at the UBS Virtual CNS Day Conference at 12:00 p.m.... Read More

TD Cowen 44 th Annual Healthcare Conference on March 5 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami Barclays 26 th Annual Global Healthcare Conference on March 13 in Miami SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in March. Matt Abernethy , Chief Financial Officer, and Kyle Gano , Chief Business... Read More

INGREZZA ® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion , Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA ® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion Crinecerfont FDA Regulatory Submission Anticipated in the Second Quarter for the Treatment of Congenital Adrenal Hyperplasia in Adults and Pediatrics SAN DIEGO ,... Read More

Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on February 7, 2024 . The schedule for the press release and conference call / webcast is as follows: •... Read More

SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco . Kevin Gorman , Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com . A replay... Read More

Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinecerfont New Drug Application Submission Planned in 2024 NBI-'770, an Oral NMDA NR2B Negative Allosteric Modulator, Entering Phase 2 for the Treatment of Major Depressive Disorder Advancing Largest Portfolio of Muscarinic Compounds in Clinical Development Top-Line Phase 2 Data Readouts for Five Programs Anticipated in 2024 Including... Read More

SAN DIEGO , Dec. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&D portfolio and strategy on Tuesday, December 5, 2023 in New York . The event will be held in-person and via webcast. It will feature Kevin Gorman , Chief Executive Officer, and Jude Onyia , Chief Scientific Officer, as well as additional... Read More

SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of INGREZZA ® (valbenazine) prior to the expiration of applicable Neurocrine... Read More

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-1065846 in Patients with Anhedonia in Major Depressive Disorder Failed to Meet its Primary Endpoint SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,... Read More

SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD ™ , an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia. Built in collaboration with clinical experts and Level Ex, "the world's leading medical video game studio," DISCOVER TD uses gameplay, artistry, and cutting-edge technology to... Read More

SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m. Greenwich Mean Time ( 10:00 a.m. Eastern Time ) in London . Kevin Gorman , Chief Executive Officer, and additional members of Neurocrine management will present at the conference. The live presentation will be webcast and may be accessed on... Read More

SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ® -HD2 study about INGREZZA ® (valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD). Interim data suggest... Read More

INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year Growth INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.82 - $1.84 Billion Crinecerfont Adult and Pediatric CAHtalyst TM Studies Met Primary Endpoint and Key Secondary Endpoints for the Treatment of Congenital Adrenal Hyperplasia Analyst Day on December 5th Focused on R&D Portfolio and Strategy SAN... Read More

Conference Call and Webcast Scheduled for Tuesday, October 31 SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on October 31, 2023 . The schedule for the press release and conference call / webcast is as follows: • Q3 2023 Press... Read More

CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adrenal Hyperplasia Key Secondary Endpoint Demonstrated a Statistically Significant Decrease from Baseline in Daily Glucocorticoid Dose while Maintaining Androgen Control Crinecerfont Was Generally Well-Tolerated Company to Host Conference Call... Read More

SAN DIEGO , Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). The analysis suggests that adolescents with classic CAH who have more elevated baseline hormone levels may... Read More

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 30, 2024 SAN DIEGO , Sept. 14, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for INGREZZA ® (valbenazine) oral granules, a new sprinkle formulation of INGREZZA ® (valbenazine) capsules for oral administration. The agency set a... Read More

CAHtalyst ™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control Key Secondary Endpoint Achieved Statistically Significant Decrease in Androstenedione at Week 4 versus Placebo Key Secondary Endpoint Demonstrated a Statistically Significant Number of Patients on Crinecerfont Achieved a Reduction to a Physiologic Glucocorticoid Dose versus Placebo... Read More

NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions NBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor... Read More

SAN DIEGO , Sept. 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants. NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist that may have the potential to... Read More

2023 Wells Fargo Healthcare Conference on September 7 in Boston Morgan Stanley 21 st Annual Global Healthcare Conference on September 12 in New York SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano , Chief Business Development and Strategy Officer, and Todd Tushla , Vice President of Investor Relations, will... Read More

SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ® -4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (TD) severity and awareness/distress as measured by the Abnormal Involuntary Movement Scale (AIMS) and patient-reported TD impact as measured by the Trajectories of Tardive Dyskinesia... Read More

Data Presented at the 2023 MDS International Congress of Parkinson's Disease and Movement Disorders ® SAN DIEGO , Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA ® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT ® -HD study, which... Read More

SAN DIEGO , Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). 1 INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an effective starting dosage that can be adjusted by a... Read More

INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.82 Billion SAN DIEGO , Aug. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales guidance for INGREZZA in 2023.... Read More

SAN DIEGO , July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon , a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. " Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter , Chairman of the Board of Neurocrine Biosciences. "Her strong... Read More

Conference Call and Webcast Scheduled for Tuesday, August 1 SAN DIEGO , July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on August 1, 2023 . The schedule for the press release and conference call / webcast is as follows: • Q2 2023 Press... Read More

SAN DIEGO , June 15, 2023 /PRNewswire/ -- Diurnal Ltd., a Neurocrine Biosciences company (Nasdaq: NBIX), today announced that it will present new post hoc analyses of Phase 3 extension study data for modified-release hydrocortisone (approved as EFMODY ® in United Kingdom and European Union), which is being investigated as a treatment for adults with congenital adrenal hyperplasia (CAH), at ENDO 2023 June 15–18 in Chicago.... Read More

SAN DIEGO , June 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 44 th Annual Global Healthcare Conference on Thursday, June 15, 2023 at 8:00 a.m. Pacific Time ( 11:00 a.m. Eastern Time ) in Dana Point, CA. Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be... Read More

SAN DIEGO , June 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA ® (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults with or without concomitant antipsychotic therapy. The data (Poster #4) were presented at 2023 Psych Congress Elevate in Las Vegas... Read More

Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2 Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status Scores at Week 12 First Phase 3... Read More

SAN DIEGO , May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of INGREZZA ® (valbenazine) capsules evaluating global tardive dyskinesia (TD) improvement and stability of psychiatric symptoms in adults with TD and schizophrenia or schizoaffective disorder. The data (Poster #SA135) was presented at the... Read More

Post Hoc Analyses of Phase 2 Study of Crinecerfont in Adults with CAH Demonstrate Androgen Reduction Across a Broad Range of Glucocorticoid Doses Post Hoc Analyses of Phase 3 Study Demonstrate EFMODY ® (hydrocortisone modified-release hard capsules) Reduced Androgen Levels Compared to Immediate-Release Hydrocortisone in Patients with CAH SAN DIEGO , May 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a... Read More

INGREZZA ® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1.77 Billion SAN DIEGO , May 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an update on its 2023 financial guidance. "INGREZZA's first quarter results... Read More

SAN DIEGO , May 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conference at 10:00 a.m. Pacific Time ( 1:00 p.m. Eastern Time ) on Tuesday, May 9, 2023 . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on Neurocrine... Read More

Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and nearly seven out of 10 people living with the condition have not yet been diagnosed 1,2 SAN DIEGO , May 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and importance of screening for tardive dyskinesia (TD), during Tardive... Read More

Conference Call and Webcast Scheduled for Wednesday, May 3 SAN DIEGO , April 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on May 3, 2023 . The schedule for the press release and conference call / webcast is as follows: • Q1 2023 Press Release:... Read More

SAN DIEGO , March 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday , March 28, 2023. Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will participate at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at... Read More

SAN DIEGO , March 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT ™ , the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (TD), was published in the Journal of Patient-Reported Outcomes . 1 The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal... Read More

SAN DIEGO , March 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube. The data (Poster #IND03, Valbenazine Capsule Contents for Potential Administration via Soft Food/Feeding Tube) will be... Read More

Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m.... Read More

SAN DIEGO , March 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc . (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA ® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT ™ 3-extension and KINECT ™ 4). These data (Poster #NR-36, Improvements Over Time with Long-Term Valbenazine in Older... Read More

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development... Read More

SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday , February 14, 2023. Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under... Read More

INGREZZA ® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 Billion Enrollment Complete in Adult and Pediatric Registrational Studies of Crinecerfont for the Treatment of Congenital Adrenal Hyperplasia Top-Line Data for Clinical Programs in Congenital Adrenal Hyperplasia, Focal Onset Seizure and Anhedonia in Major Depressive Disorder... Read More

Conference Call and Webcast Scheduled for Monday, February 6 SAN DIEGO , Jan. 17, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on February 6, 2023 . The schedule for the press release and conference call / webcast is as follows: • Q4... Read More

SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41 st Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Pacific Time on Monday Jan. 9, 2023 in San Francisco . Kevin Gorman , Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com . A replay of... Read More

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for valbenazine as a treatment for chorea associated with Huntington disease... Read More

SAN DIEGO , Dec. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous... Read More

SAN DIEGO , Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A -related epilepsies. Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure ® Program, of which Neurocrine Biosciences... Read More